7:01 AM ET
8-K
Clinical Trial Data
Traws Pharma Clinical Trial Data
Traws Pharma announced final Phase 2a results for Ratutrelvir, showing symptom resolution comparable to PAXLOVID with no viral rebound and fewer treatment-related adverse events in COVID-19 patients. The company also completed a bridging study for Tivoxavir Marboxil (TXM), supporting its potential as a once-monthly influenza prophylactic agent.